Adenovirus-mediated transduction of the herpes simplex thymidine kinase gene (HSV-tk) in conjunction with ganciclovir (GCV) has been shown to result in significant growth suppression and to enhance survival in a model of mouse prostate cancer. However, this therapeutic activity is not sustained, because in most cases tumors eventually regrow and ultimately cause the death of the host. Androgen ablation, an inducer of apoptosis in prostate cells which is used widely as palliative therapy in patients with prostate cancer, was combined with HSV-tk plus GCV using an androgen-sensitive mouse prostate cancer cell line. The combination of castration and HSV-tk plus GCV led to markedly enhanced tumor growth suppression in both subcutaneous and orthotopic models compared with either treatment alone and resulted in an enhanced survival in which combination-treated animals lived twice as long as controls in the subcutaneous model and over 50% longer than controls in the orthotopic model. Further analysis of apoptotic activity demonstrated high levels of apoptosis only in combined androgen ablation and HSV-tk plus GCV-treated tumors after 14 days of growth in an androgen-depleted environment and 8 days after HSV-tk plus GCV therapy. At this time, the apoptotic index, but not the percent of necrotic tissue, was significantly higher for combination therapy-treated tumors relative to control-treated tumors or either treatment alone. These data indicate that the therapeutic effects of androgen ablation and HSV-tk plus GCV are cooperative and that increased apoptosis may, in part, underlie these activities.
O ur group has pioneered the use of suicide gene therapy using herpes simplex virus thymidine kinase (HSV-tk) gene transduction in conjunction with ganciclovir (GCV) as an alternative treatment for prostate cancer. 1, 2 The primary method of HSV-tk plus GCV-induced cytotoxicity is through the generation of thymidine kinase-mediated phosphorylation of GCV, thereby converting it to a nondiffusible nucleoside analog, the action of which terminates DNA synthesis. 3 This system exhibits a bystander effect that is manifested by the killing of more cells than are transduced with the HSV-tk gene. 4 The direct transfer of phosphorylated GCV through gap junctions from transduced to nontransduced cells, [5] [6] [7] [8] the endocytosis by nontransduced cells of cellular vesicles from HSV-tk-infected, dying cells containing phosphorylated GCV, 4,9 the targeting of tumor vasculature endothelium, 10 and the induction of an immune response [11] [12] [13] [14] [15] have been proposed as mechanisms for the bystander phenomenon. The expanded biological activities produced through a bystander effect serve to bypass a major potential pitfall of in situ cancer gene therapy: the transduction of sufficient cells within a solid tumor to enact tumor growth suppression.
Using a replication-deficient adenovirus (AdV) as the delivery vehicle for the HSV-tk gene, we previously demonstrated GCV-dependent cytotoxicity in both human prostate cancer cell lines and a mouse prostate cancer cell line, RM-1, in vitro as well as growth suppression in established subcutaneous (s.c.) mouse prostate tumors after direct injection with the AdV/HSV vector followed by the systemic administration of GCV. 1 In an orthotopic, metastatic model of mouse prostate cancer, AdV/HSV-tk plus GCV therapy suppressed local tumor growth, enhanced animal survival, inhibited the establishment of spontaneous metastases despite the eventual regrowth of the primary tumor, and induced systemic activity against experimentally produced metastases. 2 Although these studies are encouraging, tumor cells that survive the initial treatment course ultimately regrow, leading to the eventual death of the host. Therefore, further improvements are warranted to yield better long-term local control and improved survival.
Androgen ablation, either through surgical removal of the testicles or through the use of luteinizing hormonereleasing hormone agonists, is a mainstay of prostate cancer treatment. It has been used primarily as a palliative treatment for patients with locally advanced and metastatic disease, with 70 -80% of patients having a favorable initial response. However, this initial response is short lived; androgen-independent prostate cancer generally emerges, resulting in disease progression and ultimately death in most patients who present with metastatic disease within 5 years of diagnosis. 16 Recently, androgen ablation has been used in a neoadjuvant setting for patients with locally advanced prostate cancer in combination with definitive therapies, radiation therapy, and radical prostatectomy. These treatment combinations have resulted in lower positive surgical margin rates in surgical patients and in an improvement in local control in irradiated patients. [17] [18] [19] [20] [21] [22] [23] However, long-term patient outcome benefits from these treatment combinations, such as improved overall survival, have not been demonstrated as of yet.
Studies in animals and humans have revealed that androgen ablation induces involution and growth suppression in both benign and malignant prostatic tissues, which is primarily mediated through an induction of apoptosis above the baseline rate. 24 -27 We and others have demonstrated that HSV-tk plus GCV therapy produces elevated apoptotic activities. 1, 7, 9, 28 Indeed, bystander killing of nontransduced cells by HSV-tk plus GCV seems to occur through the induction of apoptosis. 7, 9, 28 Because of the sensitivity of both normal and malignant prostatic epithelia to apoptotic stimuli, a combination of therapies whose actions are mediated in part through the induction of apoptosis could prove beneficial in the development of gene therapy for the treatment of prostate cancer. In this study, we document that the combination of androgen ablation and AdV/ HSV-tk plus GCV has cooperative effects, resulting in superior tumor growth suppression and animal survival compared with either therapy alone. This improved activity seems to be mediated in part by enhanced apoptosis.
MATERIALS AND METHODS

Mouse prostate cancer cell line
The mouse prostate cancer cell line, RM-2, was derived from a primary prostate cancer induced in the mouse prostate reconstitution (MPR) model system as described previously. 29 -31 In this system, prostate cancer is induced by infecting fetal prostate-specific urogenital sinus tissues with a helper virus-free recombinant retrovirus that transduces ras and myc oncogenes, and resulting cell lines are grown from primary tumors as explant cultures. Previous characterization demonstrated that this cell line is androgen-sensitive in vitro 31 and in vivo. 30 Cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 10 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, penicillin (100 U/mL), and streptomycin (100 mg/mL); passaged by trypsinization with 0.025% trypsin; and maintained with routine media changes. All chemicals for cell culture were obtained from Life Technologies (Gaithersburg, Md).
Adenoviral vectors
The HSV-tk gene was packaged in a replication-defective recombinant AdV under the transcriptional control of the Rous sarcoma virus (RSV) long terminal repeat promoter, as described previously. 32 This construct was identical with that used previously in studies with our mouse model of prostate cancer.
1,2 For the quantitation of transduction efficiency and to serve as a control vector, the bacterial ␤-galactosidase (␤-gal) gene along with the RSV-long terminal repeat promoter (AdV/RSV-␤-gal) was also packaged in a replication-defective recombinant AdV as described previously. 33 Recombinant AdVs were isolated from a single plaque, expanded in the 293 cell line and purified by double-cesium gradient ultracentrifugation. 34 Virus titer was determined by plaque assay in 293 cells and reported as plaque-forming units (PFU).
In vivo gene therapy
Initial in vivo studies with the combination of androgen ablation and AdV/HSV-tk were performed in the s.c. model. Previous experience using RM-1, a cell line derived from rasand myc-induced mouse prostate cancer, in the s.c. model failed to demonstrate any difference in tumor volume, wet weight (wt/wt), or survival between the vector control groups of AdV/RSV-␤-gal plus phosphate-buffered saline (PBS), AdV/ RSV-␤-gal plus GCV, and AdV/HSV-tk plus PBS. 1 Therefore, in the s.c. experiments with combination therapy AdV/HSV-tk plus PBS served as the control group. At 1 week before cell inoculation, animals were randomized to surgical castration or sham operation under sodium pentobarbital-induced anesthesia. The s.c. tumors were generated in syngeneic C57BL/6 animals as described previously.
1 Palpable s.c. tumors developed by the second day after the injection of 4 ϫ 10 6 RM-2 cells, at which time each was measured with a verniers caliper and a volume was calculated by the formula of a rotational ellipsoid (m 1 2 ϫ m 2 ϫ 0.5236, where m 1 represents the shorter axis and m 2 represents the longer axis 35 ). These established tumors were then injected with 5 ϫ 10 8 PFU of AdV/HSV-tk. This dose of virus was based on dose escalation studies reported previously. 1 On the following day, animals were randomized to receive either GCV (10 mg/kg) or PBS by intraperitoneal (i.p.) injection twice daily for 6 days. Tumors were measured every other day, generating calculated volumes for each treatment arm. Animals were monitored until death or sacrifice when signs of distress were apparent, as evidenced by weight loss, ruffled fur, or lethargy, or when tumor size reached 10% of body weight.
Because there is evidence for differential sensitivities to HSV-tk plus GCV between s.c. and orthotopic sites, 2,36 studies were also performed in the orthotopic model. Orthotopic tumors were generated by the injection of 5000 cells into the right or left dorsolateral prostate as described previously.
2 By the day 6 postinjection, tumors filled the injected lobes. Viral transduction efficiency in vivo was calculated as described previously. 1 Briefly, three tumors in sham-operated hosts were injected with 5 ϫ 10 8 PFU of AdV/RSV-␤-gal on day 6 after tumor inoculation and the animals were sacrificed 48 hours later. Tumors were frozen, fixed, and prepared for X-gal staining. The percentage of positively stained cells was quantitated and averaged with the aid of adjacent sections stained with hematoxylin and eosin (H&E). As in the s.c. model, animals for therapeutic studies were randomized to sham versus castration at 7 days before tumor inoculation. Adenoviral vectors (5 ϫ 10 8 PFU of AdV/HSV-tk or AdV/RSV-␤-gal) were injected directly into established tumors on day 6 postinoculation. Before viral injection, each tumor was measured with a vernier caliper and a volume was calculated. Beginning the following day, i.p. injections of GCV (10 mg/kg) or PBS were performed twice daily for 6 days. Animals were sacrificed on day 14 after tumor inoculation (day 8 posttreatment) or when distress was apparent. Primary tumors were excised, a wet weight was obtained, and a portion of the tumor was placed in formalin for standard histological analysis.
Preliminary work with the RM-2 cell line revealed metastatic activity in the pelvic and retroperitoneal lymph nodes of the majority of animals with orthotopic tumors without metastatic spread to the lungs as described previously for the RM-1 cell line.
2 Therefore, to ascertain the benefit of androgen ablation, AdV/HSV-tk plus GCV, and combination therapy on metastatic activity, the pelvic and retroperitoneal lymph nodes and samples of lung were excised regardless of gross appearance and processed for microscopic examination.
Histological analyses
Formalin fixed, paraffin-embedded sections were stained with H&E for routine analysis. To determine apoptotic activities in castration and AdV/HSV-tk-mediated growth suppression, sections of primary tumor tissue were prepared to stain for DNA fragmentation by the terminal deoxynucleotidyltransferase-mediated uridine 5Ј-triphosphate nick-end labeling (TUNEL) technique. 37 The extent of apoptosis was assessed quantitatively via computer-assisted image analysis (Bioscan) on 15-20 microscopic fields at ϫ200 magnification. The data were recorded as apoptotic bodies per 1000 cancer cells (defined as apoptotic index). The extent of necrosis was also assessed quantitatively on H&E-stained slides via computerassisted image analysis.
Statistical analyses
An unpaired t test was used to compare either tumor volume or tumor wt/wt between treatment groups in both the s.c. and orthotopic models. A nonparametric Kaplan-Meier plot was used to analyze survival between treatment groups in both models. Estimates of statistical significance were determined using the Mantel-Cox log-rank test. Fisher's exact test was used to evaluate the significance of the presence or absence of lymph node metastases. Apoptotic indices were compared using an unpaired t test. All statistical analyses were performed using Statview (Abacus Concepts, Berkeley, Calif).
RESULTS
s.c. model
At 2 days after the s.c. injection of RM-2 cells into mice castrated 7 days previously, the average tumor volume . All tumors were injected with AdV/HSV-tk at this time, and animals were randomized to receive either GCV or PBS injections twice daily for the next 6 days. The estimated volume of the tumors for each treatment group was monitored by measurements every other day and is presented in Figure 1 . The combination of castration and AdV/HSV-tk plus GCV had a growth-suppressive effect that persisted for ϳ3 weeks before residual viable tumor cells began to regrow at a rate similar to that of other treatment groups. Table  1 presents the tumor volume for each treatment group as determined on day 14 after cell injection. In comparison with previous studies with the RM-1 cell line, 1 RM-2 tumors were somewhat slower growing based on tumor volume at a fixed time (days 13 or 14). In this study, a significant (P ϭ .0066) difference in the tumor volume (53% that of controls) was achieved after GCV treatment. The RM-2 cell line is androgen-sensitive in vitro, 31 and tumors initiated with RM-2 cells respond to androgen ablation in vivo. 30 AdV/HSV-tk-injected tumors in castrated mice treated with PBS were ϳ80% of the volume of tumors from noncastrated mice, but this difference did not achieve statistical significance (P ϭ .415). The combination of castration and HSV-tk plus GCV therapy resulted in s.c. tumors that were significantly smaller than those with either castration alone (P ϭ .0068) or AdV/HSV-tk plus GCV alone (P ϭ .002).
The effect of combination therapy on the survival of the animals in this s.c. model is presented in Figure 2 as a Kaplan-Meier survival analysis. The mean survival time is included in Table 1 . In comparison with the control sham-operated, PBS-injected group, the improvement in survival for the PBS-injected, castrated group approached significance (P ϭ .07). AdV/HSV-tk plus GCV treatment significantly improved survival compared with controls in both the sham-operated group (P ϭ .0015) and the castrated group (P ϭ .0023). Furthermore, combination therapy resulted in a marked improvement in animal survival compared with AdV/ HSV-tk plus GCV without castration (P ϭ .011).
Orthotopic model
All virus injections were conducted on day 6 after RM-2 inoculation, at which time prostatic primary tumors filled the lobe of the prostate originally injected with no significant difference in tumor volume between sham (15.8 Ϯ 3.2 mm 3 ) and castrated animals (14.1 Ϯ 5.0 mm 3 ). The mean viral transduction efficiency in vivo was determined by staining for ␤-gal activity at 48 hours after the injection of 5 ϫ 10 8 PFU of AdV/RSV-␤-gal and was 12.4% (range, 2-31%). After the injection of 5 ϫ 10 8 PFU AdV/HSV-tk (or AdV/RSV-␤-gal as a control virus in selected experiments), animals were randomized to receive GCV or PBS i.p. injections twice daily for 6 days. Animals were sacrificed at 14 days after tumor inoculation, which was the day after the completion of GCV or PBS treatment, to evaluate tumor volume at a fixed timepoint (Table 2 and Fig 3) ; survival ( 4) was determined in a separate experiment in which animals were observed until death or sacrifice because of distress. There was no difference in tumor wt/wt at 14 days between AdV/HSV-tk plus PBS and AdV/RSV-␤-gal plus GCV treatments in sham-operated mice (data not shown); consequently, both treatments were used as controls. The AdV/HSV-tk plus GCV treatment protocol for RM-2 tumors in intact animals resulted in tumors that were 49% of the wt/wt of the controls (P ϭ .007). The effect of castration on this androgen-sensitive tumor was to reduce the size of both AdV/HSV-tk plus PBStreated and AdV/RSV-␤-gal plus GCV-treated tumors at 14 days. Both groups yielded similar results, and the average wt/wt of this combined group was 69% (P ϭ .009) of that of the control group in sham-operated mice. Combination therapy (AdV/HSV-tk plus GCV in castrated mice) resulted in tumors that were 31% of the wt/wt of control tumors (P Ͻ .0001). No gross metastases were observed in the animals sacrificed at 14 days, but histological analysis was performed on lymph nodes removed from the pelvis and retroperitoneum to detect the presence of microscopic metastases (Table 2) . None (0 of 11) of the animals that received AdV/HSV-tk plus GCV treatment had evidence of metastases, whereas 80% of the controls and the castration alone group had microscopic metastases. A separate group of animals for each treatment group was evaluated for long-term survival (Table 2 and Fig 4) . The AdV/HSV-tk plus GCV treatment protocol for RM-2 orthotopic tumors resulted in an increase in mean survival from 16.6 to 18.3 days, which was significant by the Mantel-Cox log-rank test (P ϭ .0298). The slight increase in survival to 17.3 days for castrated animals that received i.p. PBS injections after tumor injection with AdV/HSV-tk was not significant (P ϭ .35). Animals treated with combination therapy had a mean survival of 27.7 Ϯ 5.7 days, with two long-term survivors, resulting in a superior survival benefit compared with controls (P Ͻ .0001) or sham-operated AdV/HSV-tk plus GCV animals (P ϭ .0076). One animal died 63 days postinoculation, but an autopsy was not performed because of severe decomposition of the body. The second animal was sacrificed when it appeared sick at 127 days after tumor inoculation. Autopsy revealed bladder outlet obstruction and bilateral hydroureteronephrosis with no evidence of tumor within the prostate. This condition has been noted as a cause of distress and death or found unexpectedly at the time of virus injection or sacrifice. It is thought to occur from excessive manipulation of the bladder leading to denervation of the bladder and subsequent urinary retention (our unpublished observations).
Metastatic activity was detected by microscopic analysis of the lymph nodes in animals for which tissue was available from the survival study. The AdV/HSV-tk plus PBS treatment had a similar number of positive lymph nodes in the sham-operated (69%) and castrated (75%) animals. Lymphatic metastases were reduced significantly compared with controls after AdV/HSV-tk plus GCV treatment in both sham (24%, P ϭ .025) and castrated animals (5.6%, P ϭ .003), but the difference between these two did not achieve significance (P ϭ .177). Therefore, treatment with AdV/HSV-tk plus GCV regardless of androgen status resulted in a significant reduction in metastatic activity. The role of apoptosis and/or necrosis in the observed growth suppression was analyzed by the TUNEL technique (Fig 5A) and by morphometric analysis (Fig 5B) on sections of primary tumors from mice sacrificed at day 6, which was the day of virus injection, and at day 14, which was the day that GCV or PBS injections were concluded. Figure 6A presents the results of the TUNEL analysis as an apoptotic index (AI) (equals number of positive cells, i.e., apoptotic bodies, per 1000 cells). At day 6, the AI was 6.6 Ϯ 4.9 in sham-operated animals and 10.2 Ϯ 1.5 in castrated animals. By day 14, the AIs of sham and castrated tumors injected with AdV/RSV-␤-gal plus GCV and AdV/HSV-tk plus PBS were approximately equal to those at the time of virus injection (7.6 Ϯ 1.1 and 10.1 Ϯ 1.2, respectively). Treatment with AdV/HSV-tk plus GCV alone led to a 2-fold increase in AI (P ϭ .013), and combination therapy led to a 3.5-fold increase in AI (P ϭ .006). The level of necrosis within the tumors was increased ϳ5-fold in response to AdV/ HSV-tk plus GCV in both sham-operated and castrated hosts (Fig 6B) .
DISCUSSION
AdV-mediated transduction of the HSV-tk gene in conjunction with GCV therapy results in growth suppression of tumors and prolongation of survival in numerous tumor models, including the prostate.
1,2,32,36,38 -43 Whereas significant cure rates have been achieved in both brain and head and neck squamous cell cancer models, 32, 36, 40 in situ gene therapy with AdV/HSV-tk plus GCV usually produces initially high but incomplete response rates, with the subsequent outgrowth of surviving cells resulting in the death of the host in most models. Although encouraging, these findings suggest a potentially limited role of HSV-tk plus GCV as monotherapy. Advances in gene delivery systems, improvements in vector injection techniques, enhancement of immunological activities, and/or expansion of the bystander effect are viable strategies to improve HSV-tk plus GCV gene therapy.
Androgen ablation represents first-line but palliative therapy for patients with locally advanced and metastatic prostate cancer. In the normal rodent prostate, castration results in an induction of apoptosis within the glandular epithelium, with an 80% reduction in prostatic wt/wt by 10 days postcastration. 24 An examination of human prostate specimens after 3 months of androgen ablation also demonstrates an increase in apoptotic activity within both cancerous and noncancerous prostatic tissues. 25, 26 Previous studies with androgen-sensitive MPR tumors have demonstrated androgen-sensitive activities in regard to both the growth and expression of apoptosis-related genes in response to castration in vivo. 30 The MPR-derived mouse cell line, RM-2, that was used in this study is sensitive to androgens regarding growth in vitro and in vivo. 30, 31 Because the effects of HSV-tk plus GCV seem to be mediated in part by an induction of apoptosis 1, 7, 9, 28 and both normal and malignant prostatic epithelia are sensitive to castrationinduced apoptosis, the use of androgen ablation in combination with HSV-tk therapy might be expected to produce improved efficacy over either treatment alone.
In vivo, the combination of castration and AdV/ HSV-tk plus GCV resulted in growth-suppressive activities that were significantly higher than either castration alone or AdV/HSV-tk plus GCV alone as evidenced by the 14-day comparisons of tumor volume in the s.c. model and wet weight in the orthotopic model. Indeed, it seems that the growth-suppressive activities of combination therapy are the result of the addition of the individual activities of castration alone and AdV/HSV-tk plus GCV alone in both models. Although increased apoptosis was not an obvious feature in control AdV/ HSV-tk plus PBS-treated tumors grown in castrated hosts relative to sham-operated hosts, there was a marked enhancement of apoptotic activity in AdV/ HSV-tk plus GCV-treated tumors in the castrates.
The significant growth-suppressive activity of combination therapy translated into a marked enhancement (greater than additive) of survival compared with either treatment alone in this aggressive model of mouse prostate cancer; combination animals lived 100% longer in the s.c. model and over 50% longer in the orthotopic model compared with control animals as determined by mean survival times. In the orthotopic model, the combination of androgen ablation and AdV/HSV-tk plus GCV resulted in a 9% incidence of long-term survivors, Figure 6 . Apoptosis and necrosis in an orthotopic model. A: The AI was determined by the TUNEL technique on sections from tumors harvested on day 6, which was the day of virus injection, or day 14, which was the day after the completion of GCV or PBS treatment. The combination treatment group had a significantly higher level of apoptosis ‫,ء(‬ P ϭ .006). B: The percentage of each section with morphologically distinct necrotic cells was determined on sections adjacent to those used for AI detection. Significantly increased ‫,ء(‬ P Ͻ .008) necrosis was seen with AdV/HSV-tk plus GCV treatment in both sham-operated and castrated animals.
with the first documented cure of an established orthotopic prostatic tumor in this model system.
Orthotopic inoculation of the RM-2 cell line results in the development of spontaneous metastatic activity. As was demonstrated previously in the RM-1 orthotopic prostate model, 2 treatment of the primary tumor with AdV/HSV-tk plus GCV suppressed the incidence of metastasis both at the 14-day timepoint and in the survival study. Metastasis suppression was observed to the same extent in both AdV/HSV-tk plus GCV alone and combination therapy animals but not in the castration only group. Additional studies using more animals and a more sensitive analysis of metastatic activities could potentially reveal an antimetastatic castration effect. However, it seems that the enhanced benefits of combination therapy are not derived from enhanced antimetastatic activities in these studies, but are related in part to cooperative apoptotic activities. It is conceivable that castration sensitizes some tumor cells to a direct or indirect (bystander) effect produced by AdV/ HSV-tk plus GCV or alternatively that the biological activities induced by AdV/HSV-tk plus GCV potentiate castration-induced apoptosis. Further studies that would clarify the underlying mechanism(s) seem warranted.
Our results demonstrating the enhancement of therapeutic and biological endpoints with combined HSV-tk plus GCV and castration therapy parallel other recent studies using radiation therapy. Early clinical outcome data on the combination of radiation therapy and androgen ablation, both of which induce apoptosis, have shown a benefit with regard to local control and progression-free survival. 17, 18, 20, 21 Some of this benefit is thought to be derived from androgen withdrawal-mediated tumor shrinkage, resulting in smaller tumors for targeting by the radiation treatment. Further experimental studies have revealed that the dose of radiation required to control Shinogi mammary tumors can be reduced by one-third after only 24 hours of androgen ablation. 44 Therefore, the precedent for the cooperation of apoptosis-mediating treatments to attain enhanced results has been established.
Although it seems that enhanced apoptotic activity has a role in the significant growth-suppressive activities of combination therapy, other biological activities that are related or unrelated to apoptosis are likely involved. The generation of immunological activity has been implicated in the efficacy of AdV/HSV-tk plus GCV therapy in both primary tumors and challenge tumors by several investigators. 11, 12, 14 Androgen withdrawal has significant effects on the immune system. Both male and female gonadal steroids seem to regulate immune function, as evidenced by sexual differences in immune responses, altered immune responses to gonadectomy and subsequent replacement therapy, alterations during pregnancy, and the localization of receptors for gonadal steroids in organs controlling immune responses. 45 Castration induces thymic hypertrophy and an increase in the numbers of T and B cells in the spleen of the adult male mouse. 46 In male mice, challenge by T-cell-dependent antigens (sheep red blood cells) was markedly more robust in castrated animals compared with intact animals, whereas there seemed to be no such difference when challenge was made with T cell-independent antigens. 47 Overall, the data from a limited number of studies are consistent with the suppression of T-cellmediated immune responses by testosterone. Although a clearly defined role for the immune system in the local antitumor activity resulting from AdV/HSV-tk plus GCV therapy has not been established, it is conceivable that the castration-induced effects on the immune system could contribute to the markedly superior results obtained with combination therapy. Additional points of common and potentially synergistic mechanisms of action are the effects of HSV-tk plus GCV therapy on the tissue vasculature 10 and castration-induced decreases in blood vessel density 48 and vascular endothelial growth factor expression. 49 Further studies are required to delineate these possibilities.
In this study, we have shown that the combination of androgen ablation and AdV/HSV-tk plus GCV results in superior growth suppression and animal survival compared with either treatment alone. Further tissue analysis revealed that the induction of apoptotic activity is also enhanced in the combination therapy-treated tumors compared with either treatment alone. Although the distinct mechanisms for these observations are unknown, there seem to be cooperative activities between these treatment strategies. Further studies regarding the underlying mechanism(s) of action seem warranted.
